Predictors of AAA Expansion and/or Rupture
Condition: Abdominal Aortic Aneurysm (AAA)
MeSH terms: Aneurysm; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Rupture
Intervention: Assess AAA rupture risk by PET-CTA scans; 18F-fludeoxyglucose (FDG); 11C-PBR28
Intervention description: Assess AAA rupture risk by PET-CTA scans; Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging; Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
Intervention MeSH terms: Fluorodeoxyglucose F18
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Factorial Assignment
Intervention model description: Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group).
The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will compare two radiotracers, 18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging during the PET-CT scan. The investigator will also compare the results describing the mechanical properties of the AAA wall to the degree of inflammation in that wall as determined by PET-CT imaging to define new and better predictors of AAA growth and/or rupture.
Masking: None (Open Label)
Enrollment: 2.0
Sex: All
Minimum age: 45 Years
Healthy volunteers: No
Keywords: Abdominal Aortic Aneurysm (AAA)

Summary:

      Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or
      because they do not have an AAA (control group).

      The purpose of this research study is to further study, through FEA, changes that occur in
      the mechanical properties of the aortic wall. The investigator will compare two radiotracers,
      18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about
      inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging
      during the PET-CT scan. The investigator will also compare the results describing the
      mechanical properties of the AAA wall to the degree of inflammation in that wall as
      determined by PET-CT imaging to define new and better predictors of AAA growth and/or
      rupture.
    

Eligibility criteria:

        Inclusion

          -  All ethnic groups

          -  45 years of age or older

          -  *Must fit into one of the three following groups:

               -  Control group (atherosclerosis without aneurysmal disease

               -  Small AAA (3-4.5 cm)

               -  Rapidly growing AAA (0.5 cm in 6 months or 1 cm in 12 months)

        Exclusion

          -  At risk population (cognitively impaired)

          -  Any exclusion for PT-CT (i.e., allergy to contrast)

          -  Any woman planning to become pregnant, suspects pregnancy, pregnant or breastfeeding)

          -  Any greater than normal potential for cardiac arrest

          -  Renal disease (eGFR <60 mg/ml/1.73m2)

          -  Claustrophobic reactions and/or is unable to lie on the exam table for 60 minutes

          -  Significant radiation exposure via other trials or medical testing